Bacterial Antigen Ingredients TRIZ Cases

Engineered botulinum neurotoxin C1 light chain polypeptides selectively cleave syntaxin protein through modified amino acid sequences in the catalytic pocket.

Lambda red recombinase enables stable chromosomal insertion of large DNA fragments without antibiotic selection pressure.

Catheter-based delivery of toxins or radioactive agents inactivates airway smooth muscle tissue, reducing airway constriction without systemic side effects.

Butyribacter intestini TF01-11 resolves medication toxicity by using probiotics to lower obesity risks without side effects.

Segmented enolase peptide antigen blocks plasminogen interaction to inhibit malaria parasite proliferation.

Excluding serotype 6A reduces vaccine valence while maintaining broad protection against pneumococcal disease.

Purified multimeric protein complex from P. gingivalis induces targeted immune response against virulence factors, preventing periodontal bone loss.

Replacing the labile phosphodiester bond with a phosphoether linkage prevents hydrolysis, enabling shelf-stable liquid vaccines without cold storage.

Chromosomal antigen integration in Listeria vectors elicits cell-mediated immunity against intracellular pathogens without antibiotic resistance markers.

A Ruminococcus spp. composition alleviates liver injury by modulating gut microbiota and bile acid metabolism.

Dam and sifA gene mutations in the live attenuated Salmonella vaccine reduce shedding while maintaining broad serotype protection.

A stable heptavalent vaccine composition maintains antibody titers through specific adjuvant adsorption of multiple antigens.

Modified binary bacterial toxins bypass endosomal trapping to deliver therapeutic molecules directly into the cytosol.

Targeted probiotic supplementation during gestation strengthens offspring antigen response, resolving the gap in conventional nutritional interventions.

A digital ELISA immunoassay uses differential antibody binding to quantify Clostridium difficile toxin B levels in clinical samples.

Peripheral blood mononuclear cells replace complex dendritic cell isolation, enabling cost-effective multi-organism vaccine screening and prophylactic use.

Bivalent linker joins native outer membrane vesicle surface saccharides to antigens, avoiding detergent-induced protein alteration and vesicle aggregation.

Asymmetrical microparticles mimic dendritic cell geometry to enhance T cell activation and proliferation.

Combination vaccine uses IgM protease antigen and bacterin to protect pigs against inconsistent serotype coverage.

Prime-boost KMP11 vectors overcome ineffective existing vaccines by inducing CD4 and CD8 T cell proliferation to prevent parasite diffusion.

Multi-epitope DNA vaccines induce CD4 and CD8 immune responses using PLGA microparticle delivery.

Chitosan and anionic polymers form a mucoadhesive matrix that protects antigens from gastric acid and releases them at the intestinal mucosa.

D-peptide hydrogels recruit CD11b+ cells and boost tensile strength, resolving unpredictable biological activity in wound healing.

Live bacterial therapeutics displaying pathogen associated molecular patterns stimulate immune cells to enhance checkpoint inhibitor efficacy.

Replacing swine serum with reduced media lowers costs and eliminates pathogen contamination risks during mycoplasma cultivation.

Liposomal vaccine adjuvants using DPPC and cholesterol prevent immunogenicity loss during freezing, replacing unstable aluminum salts.

An immunogenic composition targeting the 40 kDa Adhesin protein induces protective immunity against Fusobacterium infections.

Sequencing 16S ribosomal DNA isolates dominant P. acnes strains, enabling personalized treatments that reduce side effects from generic antibiotics.

Fusion proteins combine multiple Mycobacterium tuberculosis antigens to overcome BCG vaccine limitations in preventing latent infection reactivation.

Segmented Ripr polypeptide fragments act as vaccine antigens to inhibit malaria parasite growth while optimizing immunological activity.

Oral Enterococcus gallinarum strains reduce tumor size by modulating the immune system to address inadequate existing cancer therapies.

A multivalent vaccine combines PCV2 and Mycoplasma antigens with saponin adjuvants for single-dose administration.

Lactobacillus plantarum K21 resolves variable strain efficacy by downregulating COX-2 mRNA to treat metabolic disorders.

Peptide-based immunogenic compositions block faecal shedding of MAP by targeting specific antigens, preventing chronic infection cycles in livestock and humans.

Polysaccharide-protein conjugates resolve limited serotype coverage by combining multiple GBS strains to prevent late-onset disease in vulnerable populations.

Recombinant flagellin fusion protein activates toll-like receptor 5 to enhance immunity and improve aging-related functional deficiencies.

Dry cholera vaccine formulations maintain potency at ambient temperatures by reducing water activity to 0.15, eliminating cold chain dependency.

A combination product uses a non-human antigenic polypeptide to elicit a strong immune response against tumors.

Covalent lipid anchors attach antigens to liposomes, resolving weak immunogenicity and masked epitopes in HIV gp41 delivery.

Hollow silica nanospheres use porous shells to load antigens while preventing leakage, inducing specific immune responses.

PglL ComP O-oligosaccharyltransferase attaches capsular polysaccharides to pilin-like protein ComP.

Photochemical crosslinking with psoralen and UV light preserves epitopes, eliciting stronger antibody responses than formalin-killed vaccines.

Administering specific lactic acid bacteria strains establishes a protective gut environment that reduces pathogen presence during early weaning transitions.

A chimeric polyepitope recombinant antigen vaccine formulation incorporating OspA and OspC antigens from multiple Borrelia species.

Engineered diatoms express heterologous antigens while their silica cell wall acts as an adjuvant.

Plasmid vectors control peptide display density on MS2 virus-like particles using single-chain dimer coat proteins.

A vaccine formulation combining IgM protease antigen of serotype 7 with Streptococcus suis bacterin serotype 9 sequence type 16.